Clinical trial Recruiting at 2 sites Phase 1 Interventional Ages 19 to 54

Bioequivalence test of two drugs in healthy adults

Official title: An Open-lable, Randomized, Fasting, Single-dose, Oral Administration, 2-sequence, 4-period, Replicate Crossover Study to Evaluate Bioequivalence Between YHP2508A and YHR2601 in Healthy Subjects

Run by Yuhan Corporation · NCT07912827 · Data updated 2026-11-12

This study tests whether YHP2508A and YHR2601 are bioequivalent in healthy volunteers.

More Healthy Subjects (HS) trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages19 Years to 54 Years
SexAll
Enrollment44 (estimated)
SponsorYuhan Corporation
Industry-sponsored
Locations2 sites (Seoul and 1 other locations)
StatusRecruiting
StartedOctober 20, 2026
Main results expectedFebruary 2, 2027
Study endsFebruary 2, 2027
Registry record updatedNovember 3, 2026
Trial IDNCT07912827 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy adults aged generally within BMI 18-30 kg/m2 without significant diseases.

Probably not a fit

Individuals with undisclosed chronic conditions or those who do not meet the eligibility criteria may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, open-label, randomized, fasting, single-dose, oral crossover study in healthy adults. Participants are assigned to two groups and receive both drugs in different sequences across four periods to compare how the body processes each drug. The trial uses two 2-sequence, 4-period replicate crossover designs to determine bioequivalence. About 44 healthy subjects will be enrolled to ensure reliable comparison. The study aims to determine if the two formulations behave similarly in pharmacokinetics.

Why it matters

Potential benefit: If successful, patients could have access to equivalent therapeutic options with similar pharmacokinetic profiles.

How similar studies have gone: Bioequivalence studies using replicated crossover designs are commonly used to compare formulations and have shown success in similar settings.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* BMI 18-30 kg/m2
* Those without clinically significant congenital or chronic diseases

Exclusion Criteria:

* Those who have participated in a bioequivalence study or other clinical trials and have been administered investigational products within 6 months prior to the first administration
* Those who are judged ineligible to participate in the trial by the principal investigator
* Female volunteers who are pregnant, suspected to be pregnant or breathfeeding

Where it's running

  • H+ Yangji Hospital
    Seoul, South Korea
    Recruiting
  • H+ Yangji Hospital
    Seoul, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.